Abstract | PURPOSE: PATIENTS AND METHODS: A total of 637 patients with refractory or sensitive SCLC were randomly assigned at a ratio of 2:1 to 21-day cycles of amrubicin 40 mg/m(2) intravenously (IV) on days 1 to 3 or topotecan 1.5 mg/m(2) IV on days 1 to 5. Primary end point was overall survival (OS); secondary end points included overall response rate (ORR), progression-free survival (PFS), and safety. RESULTS: Median OS was 7.5 months with amrubicin versus 7.8 months with topotecan (hazard ratio [HR], 0.880; P = .170); in refractory patients, median OS was 6.2 and 5.7 months, respectively (HR, 0.77; P = .047). Median PFS was 4.1 months with amrubicin and 3.5 months with topotecan (HR, 0.802; P = .018). ORR was 31.1% with amrubicin and 16.9% with topotecan (odds ratio, 2.223; P < .001). Grade ≥ 3 treatment-emergent adverse events in the amrubicin and topotecan arms were: neutropenia (41% v 54%; P = .004), thrombocytopenia (21% v 54%; P < .001), anemia (16% v 31%; P < .001), infections (16% v 10%; P = .043), febrile neutropenia (10% v 3%; P = .003), and cardiac disorders (5% v 5%; P = .759); transfusion rates were 32% and 53% (P < .001), respectively. NQO1 polymorphisms did not influence safety outcomes. CONCLUSION:
Amrubicin did not improve survival when compared with topotecan in the second-line treatment of patients with SCLC. OS did not differ significantly between treatment groups, although an improvement in OS was noted in patients with refractory disease treated with amrubicin.
|
Authors | Joachim von Pawel, Robert Jotte, David R Spigel, Mary E R O'Brien, Mark A Socinski, Jörg Mezger, Martin Steins, Léon Bosquée, Jeffrey Bubis, Kristiaan Nackaerts, José M Trigo, Philip Clingan, Wolfgang Schütte, Paul Lorigan, Martin Reck, Manuel Domine, Frances A Shepherd, Shaoyi Li, Markus F Renschler |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 32
Issue 35
Pg. 4012-9
(Dec 10 2014)
ISSN: 1527-7755 [Electronic] United States |
PMID | 25385727
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 by American Society of Clinical Oncology. |
Chemical References |
- Anthracyclines
- Antineoplastic Agents
- Topotecan
- amrubicin
- NAD(P)H Dehydrogenase (Quinone)
- NQO1 protein, human
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Anthracyclines
(administration & dosage)
- Antineoplastic Agents
(administration & dosage)
- Disease-Free Survival
- Female
- Genotype
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms
(drug therapy, mortality)
- Male
- Middle Aged
- NAD(P)H Dehydrogenase (Quinone)
(genetics)
- Odds Ratio
- Polymorphism, Single Nucleotide
- Proportional Hazards Models
- Small Cell Lung Carcinoma
(drug therapy, mortality)
- Topotecan
(administration & dosage)
- Treatment Outcome
- Young Adult
|